ClinicalTrials.gg
CompletedNCT03845517Updated Sep 5, 2024Results posted

A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

A Phase 2 interventional study of Placebo and PF-06700841 15 mg in Systemic Lupus Erythematosus, sponsored by Pfizer. Completed at 164 sites in 26 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-09-05.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
350
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 477 studies in Lupus Erythematosus, Systemic with a site in United States — 87 open to participants now, 127 under way, 28 of them phase 3. Lupus Erythematosus, Systemic · United States.

Enrollment
60th of 407
350 · median 70
Started
2019
with 18 others
Phase 2
120 of 477
10 open now
Registered
282nd of 477
by date

Among the 477 studies in Lupus Erythematosus, Systemic with a site in United States, this one is the 60th largest by enrollment of the 407 interventional ones that give a count, is one of 19 that started in 2019, is one of 120 in phase 2, and was the 282nd registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

87 of the 477 studies in Lupus Erythematosus, Systemic with a site in United States are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 477 studies in Lupus Erythematosus, Systemic with a site in United States, or all of them as a file.
02

Study summary

Assessment of PF-06700841 in participants with moderate to severe active, generalized Systemic Lupus Erythematosus (SLE) that have inadequate response to standard of care.

03

Conditions studied

  • Systemic Lupus Erythematosus
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and/or female subjects between ≥18 and ≤75 years of age inclusive.
  • Diagnosis of moderate to severe active Lupus.
  • Receiving a stable dose of methotrexate, azathioprine, leflunomide, mizoribine, mycophenolate/mycophenolic acid, anti-malarials or .

Exclusion criteria

Exclusion Criteria:

  • Active renal lupus
  • Severe active central nervous system (CNS) lupus
  • Have cancer or a history of cancer within 5 years of screening.
  • Have a history of thrombosis (venous or arterial) or other vascular complications within the last 6 months, or any history of either recurrent thrombosis or a pulmonary embolus.
  • Active bacterial, viral, fungal, mycobacterial or other infections
  • Psychiatric condition including recent or active suicidal ideation or behavior
  • Have active fibromyalgia/myofascial/chronic pain.
  • Pregnant female subjects; breastfeeding female subjects; females subjects planning to become pregnant during the study; fertile male subjects and who are unwilling or unable to use a highly effective method of .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
350 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

  • Experimental
    PF-06700841 15 mg

    PF-06700841 15 mg

    Drug: PF-06700841 15 mg

  • Experimental
    PF-06700841 30 mg

    PF-06700841 30 mg

    Drug: PF-06700841 30 mg

  • Experimental
    PF-06700841 45 mg

    PF-06700841 45 mg

    Drug: PF-06700841 45 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving SLE Responder Index (SRI) Change of 4 (SRI-4) at Week 52

    SRI-4 components included Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), British Isles Lupus Assessment Group (BILAG) 2004 and Physician's Global Assessment (PhGA). Participants were classified as SRI-4 responders, if they met all of the following criteria compared with baseline: 1) greater than or equal to (\>=) 4 point reduction in SLEDAI-2K score; 2) no new BILAG A organ domain score or 2 new BILAG B organ domain scores; 3) no worsening (less than \[\<\] 0.3 point increase) in PhGA score. SLEDAI-2K: assesses improvement in disease activity (range: 0 to 105; higher score = higher severity). BILAG: assesses disease extent, severity in individual organ system (range: A \[severe\] to E \[no disease\]; higher score = less severity). PhGA: assesses worsening in participant's general health status (range: 0 \[none\] to 3 \[severe\]; higher score = higher severity).

    Time frame: Week 52

Secondary outcomes

  1. Percentage of Participants Achieving British Isles Lupus Assessment Group-Based Composite Lupus Assessment (BICLA) at Week 52

    BICLA included: BILAG-2004, SLEDAI-2K and PhGA. Participants were classified as responders, if they met all the following criteria: BILAG-2004 improvement (all A scores at baseline improved to B/C/D and all B scores improved to C or D); no worsening in disease activity (no new BILAG-2004 A scores or =\<1 new B score); no worsening of total SLEDAI-2K score; no significant deterioration (\<10 percent \[%\] worsening) in analogue PhGA. SLEDAI-2K: assesses improvement in disease activity (range: 0 to 105; higher score = higher severity). BILAG: assesses disease extent, severity in individual organ system (range: A \[severe\] to E \[no disease\]; higher score = less severity). PhGA: assesses worsening in participant's general health status (range: 0 \[none\] to 3 \[severe\]; higher score = higher severity).

    Time frame: Week 52

  2. Percentage of Participants Achieving Lupus Low Disease Activity State (LLDAS) at Week 52

    LLDAS was defined as SLE disease activity index (SLEDAI-2k \<=4, with no activity in major organ systems \[renal, central nervous system, cardiopulmonary, vasculitis, fever\]) and no haemolytic anaemia or gastrointestinal activity; no new lupus disease activity compared with the previous assessment; a Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-SLEDAI PhGA (scale 0-3; higher scores = higher severity) \<=1; a current prednisolone (or equivalent) dose \<=7.5 milligram per day (mg/daily); and well tolerated standard maintenance doses of immunosuppressive drugs and approved biological agents.

    Time frame: Week 52

  3. Percentage of Participants Achieving a Reduction in Prednisone (or Equivalent) Dose to <=7.5 mg/Day and Sustained for 12 Weeks Prior to Week 52 in Participants on Prednisone >7.5 mg/Day (or Equivalent) at Baseline

    In this outcome measure data is reported for participants who achieved a reduction in prednisone (or equivalent) dose to \<=7.5 mg/day and sustained for 12 Weeks prior at Week 52 and they also sustained this dose reduction for 12 weeks prior to Week 52 (Week 40 to Week 52).

    Time frame: Week 52 for achieving reduction in dose along with Week 40 to Week 52 for sustained dosing

  4. Percentage of Participants Achieving a SRI-4 Response With Prednisone Dose Reduced to <=7.5 mg/Day and Sustained for 12 Weeks at Week 52 in Participants on Prednisone >7.5 mg/Day (or Equivalent) at Baseline

    In this outcome measure data is reported for participants who achieved a reduction in SRI-4 response with prednisone dose reduced to \<=7.5 mg/day and sustained for 12 weeks at Week 52.

    Time frame: 12 Weeks prior at Week 52 (Week 40 to Week 52)

  5. Percentage of Participants With >= 50% Reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) Score at Week 52 in Participants With Baseline CLASI-A Score >=10

    CLASI is an validated measurement instrument for lupus erythematosus developed for use in clinical studies that consists of separate scores for the activity of the disease (CLASI-A). The CLASI activity score is calculated on the basis of erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and non-scarring alopecia. The CLASI activity score ranges from 0-70, with higher scores indicating more severe skin disease. Severity categories based on the CLASI activity score are as follows: mild (0-9), moderate (10-20), and severe (21-70).

    Time frame: Week 52

  6. Change From Baseline in Total Scores of Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at Week 52

    The FACIT-F Scale is a participant completed questionnaire consisting of 13 items that assess fatigue. Participants responded to each item on a 5-point scale based on their experience of fatigue during the past 7 days (0 = not at all; 1 = a little bit; 2 =somewhat; 3 = quite a bit; 4 = very much). Instrument scoring yielded a range from 0 to 52 (negatively worded items were reversed during analysis), with higher scores representing better participant status (less fatigue).

    Time frame: Baseline, Week 52

  7. Change From Baseline in Physical Health Domain Scores of Lupus Quality of Life (LupusQoL) at Week 52

    The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others; measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Physical health domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.

    Time frame: Baseline, Week 52

  8. Change From Baseline in Emotional Health Domain Scores of LupusQoL at Week 52

    The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Emotional health domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.

    Time frame: Baseline, Week 52

  9. Change From Baseline in Body Image Domain Scores of LupusQoL at Week 52

    The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Body image domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.

    Time frame: Baseline, Week 52

  10. Change From Baseline in Pain Domain Scores of LupusQoL at Week 52

    The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Pain domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.

    Time frame: Baseline, Week 52

  11. Change From Baseline in Planning Domain Scores of LupusQoL at Week 52

    The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Planning domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.

    Time frame: Baseline, Week 52

  12. Change From Baseline in Fatigue Domain Scores of LupusQoL at Week 52

    The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Fatigue domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.

    Time frame: Baseline, Week 52

  13. Change From Baseline in Intimate Relationship Domain Scores of LupusQoL at Week 52

    The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Intimate relationship domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.

    Time frame: Baseline, Week 52

  14. Change From Baseline in Burden to Others Domain Scores of LupusQoL at Week 52

    The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Burden to others domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.

    Time frame: Baseline, Week 52

  15. Incidence Rate of Severe Flare Event

    Incidence rate was defined as the number of new events per 100 person-years.

    Time frame: Week 52

  16. Number of Participants With Treatment-Emergent Adverse Events (AE)

    An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. TEAEs are events from first dose of study intervention to 4 weeks after last dose of study intervention that were absent before treatment or that worsened relative to pre-treatment state. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and all non-SAEs.

    Time frame: Day 1 of dosing up to 4 weeks after last dose of study drug (maximum treatment was up to 52 weeks, follow-up up to 56 weeks)

  17. Number of Participants With Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: Day 1 of dosing up to 4 weeks after last dose of study drug (maximum treatment was up to 52 weeks, follow-up up to 56 weeks)

  18. Number of Participants With Adverse Events Leading to Discontinuation From Study

    An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. In this outcome measure, participants with adverse events leading to discontinuation from study were reported.

    Time frame: Day 1 of dosing up to 4 weeks after last dose of study drug (maximum treatment was up to 52 weeks, follow-up up to 56 weeks)

  19. Number of Participants With Clinically Significant Vital Signs Abnormalities

    Vital signs included blood pressure, pulse rate, respiratory rate, and temperature. Clinical significance in vital signs abnormalities was judged by investigator.

    Time frame: Day 1 of dosing up to 4 weeks after last dose of study drug (maximum treatment was up to 52 weeks, follow-up up to 56 weeks)

  20. Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities

    Clinical significance in ECG abnormalities was judged by investigator.

    Time frame: Day 1 of dosing up to 4 weeks after last dose of study drug (maximum treatment was up to 52 weeks, follow-up up to 56 weeks)

  21. Number of Participants With Laboratory Test Abnormalities

    Hematology (Hemoglobin\[hgb\], hematocrit, erythrocytes\[ery\]:\<0.8\*lower limit of normal\[LLN\];reticulocytes, reticulocytes/ery:\<0.5\*LLN,\>1.5\*upper LN\[ULN\];ery mean corpuscular volume\[EMC\], EMC hgb:\<0.9\*LLN,\>1.5\*ULN;EMC hgb concentration:\<0.9\* LLN;platelet:\<0.5\*LLN;leukocytes\[leu\]:\<0.6\*LLN,\>1.5\*ULN;lymphocytes, lymphocytes/leu, neutrophils, neutrophils/leu:\<0.8\* LLN,\>1.2\*ULN;basophils, basophils/leu, eosinophils, eosinophils/leu, monocytes, monocytes/leu:\>1.2\*ULN;activated partial thromboplastin time\[PTT\], PTT, prothrombin time:\>1.1\*ULN);Clinical chemistry (Total/direct/indirect bilirubin, glucose-fasting:\>1.5\*ULN; aspartate aminotransferase\[AT\], alanine AT:\>3.0\*ULN; protein, albumin, HDL cholesterol:\<0.8\*LLN;urea nitrogen, creatinine, triglyceride, cholesterol:\>1.3\*ULN;urate, LDL cholesterol:\>1.2\*ULN;potassium:\<0.9\*LLN,\>1.1\*ULN;calcium, bicarbonate:\<0.9\*LLN;creatine kinase:\>2.0\*ULN);Urinalysis (pH\<4.5;glucose, protein, hgb, ketones, nitrite, leu esterase, granular/hyaline/WBCs casts:\>1).

    Time frame: Day 1 of dosing up to 4 weeks after last dose of study drug (maximum treatment was up to 52 weeks, follow-up up to 56 weeks)

07

Results

Posted Sep 5, 2024
Limitations and caveats
For the PF-06700841 30 mg, there was a total of 1 death which was reported in both on-treatment and follow-up phases in participant flow section.

Participant flow

A total of 350 participants with active systemic lupus erythematosus (SLE) were enrolled and randomized in the study.

Treatment Period (52 Weeks)
Participant flow — Treatment Period (52 Weeks)
MilestonePlaceboPF-06700841 15 mgPF-06700841 30 mgPF-06700841 45 mg
Started1005010199
Completed68367871
Not completed32142328
Withdrew: Adverse event1271017
Withdrew: Death0010
Withdrew: Lack of efficacy8134
Withdrew: Lost to follow-up2010
Withdrew: Non-compliance with study drug1000
Withdrew: Physician's decision0010
Withdrew: Site terminated by sponsor2000
Withdrew: Other2000
Withdrew: Pregnancy1001
Withdrew: Protocol violation0011
Withdrew: Withdrawal by subject4665
Follow-up Period (4 Weeks)
Participant flow — Follow-up Period (4 Weeks)
MilestonePlaceboPF-06700841 15 mgPF-06700841 30 mgPF-06700841 45 mg
Started1005010199
Completed89428992
Not completed118127
Withdrew: Adverse event4202
Withdrew: Death0011
Withdrew: Lost to follow-up2120
Withdrew: Physician's decision0011
Withdrew: Study terminated by sponsor0001
Withdrew: Other1010
Withdrew: Pregnancy1000
Withdrew: Protocol violation0001
Withdrew: Withdrawal by subject3571

Outcome measures

PrimaryPercentage of Participants Achieving SLE Responder Index (SRI) Change of 4 (SRI-4) at Week 52

SRI-4 components included Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), British Isles Lupus Assessment Group (BILAG) 2004 and Physician's Global Assessment (PhGA). Participants were classified as SRI-4 responders, if they met all of the following criteria compared with baseline: 1) greater than or equal to (\>=) 4 point reduction in SLEDAI-2K score; 2) no new BILAG A organ domain score or 2 new BILAG B organ domain scores; 3) no worsening (less than \[\<\] 0.3 point increase) in PhGA score. SLEDAI-2K: assesses improvement in disease activity (range: 0 to 105; higher score = higher severity). BILAG: assesses disease extent, severity in individual organ system (range: A \[severe\] to E \[no disease\]; higher score = less severity). PhGA: assesses worsening in participant's general health status (range: 0 \[none\] to 3 \[severe\]; higher score = higher severity).

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving SLE Responder Index (SRI) Change of 4 (SRI-4) at Week 52
Percentage of participantsPlaceboPF-06700841 15 mgPF-06700841 30 mgPF-06700841 45 mg
Percentage of Participants Achieving SLE Responder Index (SRI) Change of 4 (SRI-4) at Week 5264.6 (54.5 to 74.7)57.4 (42.2 to 72.6)69.7 (60.1 to 79.3)66.3 (56.1 to 76.5)
Statistical analysis
  • Placebo vs PF-06700841 15 mg · Cochran-Mantel-Haenszel · p = 0.8076 (One sided p-value.) · Risk difference (rd): -7.5 · 95% CI -24.5 to 9.5
  • Placebo vs PF-06700841 30 mg · Cochran-Mantel-Haenszel · p = 0.2189 (One sided p-value.) · Risk difference (rd): 5.2 · 95% CI -7.9 to 18.3
  • Placebo vs PF-06700841 45 mg · Cochran-Mantel-Haenszel · p = 0.4010 (One sided p-value.) · Risk difference (rd): 1.7 · 95% CI -11.8 to 15.3
SecondaryPercentage of Participants Achieving British Isles Lupus Assessment Group-Based Composite Lupus Assessment (BICLA) at Week 52

BICLA included: BILAG-2004, SLEDAI-2K and PhGA. Participants were classified as responders, if they met all the following criteria: BILAG-2004 improvement (all A scores at baseline improved to B/C/D and all B scores improved to C or D); no worsening in disease activity (no new BILAG-2004 A scores or =\<1 new B score); no worsening of total SLEDAI-2K score; no significant deterioration (\<10 percent \[%\] worsening) in analogue PhGA. SLEDAI-2K: assesses improvement in disease activity (range: 0 to 105; higher score = higher severity). BILAG: assesses disease extent, severity in individual organ system (range: A \[severe\] to E \[no disease\]; higher score = less severity). PhGA: assesses worsening in participant's general health status (range: 0 \[none\] to 3 \[severe\]; higher score = higher severity).

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving British Isles Lupus Assessment Group-Based Composite Lupus Assessment (BICLA) at Week 52
Percentage of participantsPlaceboPF-06700841 15 mgPF-06700841 30 mgPF-06700841 45 mg
Percentage of Participants Achieving British Isles Lupus Assessment Group-Based Composite Lupus Assessment (BICLA) at Week 5243.8 (33.3 to 54.2)42.6 (27.4 to 57.8)52.5 (42.2 to 62.9)53.3 (42.5 to 64.0)
Statistical analysis
  • Placebo vs PF-06700841 15 mg · Cochran-Mantel-Haenszel · p = 0.5950 (One sided p-value.) · Risk difference (rd): -2.1 · 95% CI -19.1 to 14.9
  • Placebo vs PF-06700841 30 mg · Cochran-Mantel-Haenszel · p = 0.1125 (One sided p-value.) · Risk difference (rd): 8.6 · 95% CI -5.3 to 22.6
  • Placebo vs PF-06700841 45 mg · Cochran-Mantel-Haenszel · p = 0.0891 (One sided p-value.) · Risk difference (rd): 9.6 · 95% CI -4.4 to 23.6
SecondaryPercentage of Participants Achieving Lupus Low Disease Activity State (LLDAS) at Week 52

LLDAS was defined as SLE disease activity index (SLEDAI-2k \<=4, with no activity in major organ systems \[renal, central nervous system, cardiopulmonary, vasculitis, fever\]) and no haemolytic anaemia or gastrointestinal activity; no new lupus disease activity compared with the previous assessment; a Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-SLEDAI PhGA (scale 0-3; higher scores = higher severity) \<=1; a current prednisolone (or equivalent) dose \<=7.5 milligram per day (mg/daily); and well tolerated standard maintenance doses of immunosuppressive drugs and approved biological agents.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Lupus Low Disease Activity State (LLDAS) at Week 52
Percentage of participantsPlaceboPF-06700841 15 mgPF-06700841 30 mgPF-06700841 45 mg
Percentage of Participants Achieving Lupus Low Disease Activity State (LLDAS) at Week 5222.6 (13.5 to 31.6)21.3 (8.5 to 34.0)35.1 (25.0 to 45.1)34.1 (23.6 to 44.6)
SecondaryPercentage of Participants Achieving a Reduction in Prednisone (or Equivalent) Dose to <=7.5 mg/Day and Sustained for 12 Weeks Prior to Week 52 in Participants on Prednisone >7.5 mg/Day (or Equivalent) at Baseline

In this outcome measure data is reported for participants who achieved a reduction in prednisone (or equivalent) dose to \<=7.5 mg/day and sustained for 12 Weeks prior at Week 52 and they also sustained this dose reduction for 12 weeks prior to Week 52 (Week 40 to Week 52).

Time frame:
Week 52 for achieving reduction in dose along with Week 40 to Week 52 for sustained dosing
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a Reduction in Prednisone (or Equivalent) Dose to <=7.5 mg/Day and Sustained for 12 Weeks Prior to Week 52 in Participants on Prednisone >7.5 mg/Day (or Equivalent) at Baseline
Percentage of participantsPlaceboPF-06700841 15 mgPF-06700841 30 mgPF-06700841 45 mg
Percentage of Participants Achieving a Reduction in Prednisone (or Equivalent) Dose to <=7.5 mg/Day and Sustained for 12 Weeks Prior to Week 52 in Participants on Prednisone >7.5 mg/Day (or Equivalent) at Baseline26.4 (13.6 to 39.2)36.4 (18.4 to 54.3)37.0 (21.9 to 52.0)41.9 (26.0 to 57.8)
SecondaryPercentage of Participants Achieving a SRI-4 Response With Prednisone Dose Reduced to <=7.5 mg/Day and Sustained for 12 Weeks at Week 52 in Participants on Prednisone >7.5 mg/Day (or Equivalent) at Baseline

In this outcome measure data is reported for participants who achieved a reduction in SRI-4 response with prednisone dose reduced to \<=7.5 mg/day and sustained for 12 weeks at Week 52.

Time frame:
12 Weeks prior at Week 52 (Week 40 to Week 52)
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a SRI-4 Response With Prednisone Dose Reduced to <=7.5 mg/Day and Sustained for 12 Weeks at Week 52 in Participants on Prednisone >7.5 mg/Day (or Equivalent) at Baseline
Percentage of participantsPlaceboPF-06700841 15 mgPF-06700841 30 mgPF-06700841 45 mg
Percentage of Participants Achieving a SRI-4 Response With Prednisone Dose Reduced to <=7.5 mg/Day and Sustained for 12 Weeks at Week 52 in Participants on Prednisone >7.5 mg/Day (or Equivalent) at Baseline20.8 (8.9 to 32.6)30.3 (13.1 to 47.5)32.6 (18.0 to 47.2)32.6 (17.4 to 47.7)
SecondaryPercentage of Participants With >= 50% Reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) Score at Week 52 in Participants With Baseline CLASI-A Score >=10

CLASI is an validated measurement instrument for lupus erythematosus developed for use in clinical studies that consists of separate scores for the activity of the disease (CLASI-A). The CLASI activity score is calculated on the basis of erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and non-scarring alopecia. The CLASI activity score ranges from 0-70, with higher scores indicating more severe skin disease. Severity categories based on the CLASI activity score are as follows: mild (0-9), moderate (10-20), and severe (21-70).

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With >= 50% Reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) Score at Week 52 in Participants With Baseline CLASI-A Score >=10
Percentage of participantsPlaceboPF-06700841 15 mgPF-06700841 30 mgPF-06700841 45 mg
Percentage of Participants With >= 50% Reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) Score at Week 52 in Participants With Baseline CLASI-A Score >=1073.9 (53.8 to 94.0)58.3 (26.3 to 90.4)77.8 (60.2 to 95.3)56.3 (28.8 to 83.7)
SecondaryChange From Baseline in Total Scores of Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at Week 52

The FACIT-F Scale is a participant completed questionnaire consisting of 13 items that assess fatigue. Participants responded to each item on a 5-point scale based on their experience of fatigue during the past 7 days (0 = not at all; 1 = a little bit; 2 =somewhat; 3 = quite a bit; 4 = very much). Instrument scoring yielded a range from 0 to 52 (negatively worded items were reversed during analysis), with higher scores representing better participant status (less fatigue).

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Total Scores of Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at Week 52
Units on a scalePlaceboPF-06700841 15 mgPF-06700841 30 mgPF-06700841 45 mg
Change From Baseline in Total Scores of Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at Week 524.6 (2.5 to 6.6)7.4 (4.5 to 10.2)5.8 (3.8 to 7.8)7.6 (5.5 to 9.7)
SecondaryChange From Baseline in Physical Health Domain Scores of Lupus Quality of Life (LupusQoL) at Week 52

The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others; measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Physical health domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Physical Health Domain Scores of Lupus Quality of Life (LupusQoL) at Week 52
Units on a scalePlaceboPF-06700841 15 mgPF-06700841 30 mgPF-06700841 45 mg
Change From Baseline in Physical Health Domain Scores of Lupus Quality of Life (LupusQoL) at Week 5211.585 (7.475 to 15.695)10.892 (5.241 to 16.544)12.371 (8.464 to 16.278)14.875 (10.748 to 19.002)
SecondaryChange From Baseline in Emotional Health Domain Scores of LupusQoL at Week 52

The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Emotional health domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Emotional Health Domain Scores of LupusQoL at Week 52
Units on a scalePlaceboPF-06700841 15 mgPF-06700841 30 mgPF-06700841 45 mg
Change From Baseline in Emotional Health Domain Scores of LupusQoL at Week 528.113 (4.132 to 12.093)10.469 (4.968 to 15.969)7.547 (3.749 to 11.346)11.823 (7.806 to 15.840)
SecondaryChange From Baseline in Body Image Domain Scores of LupusQoL at Week 52

The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Body image domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Body Image Domain Scores of LupusQoL at Week 52
Units on a scalePlaceboPF-06700841 15 mgPF-06700841 30 mgPF-06700841 45 mg
Change From Baseline in Body Image Domain Scores of LupusQoL at Week 529.207 (4.352 to 14.062)10.935 (4.070 to 17.799)8.169 (3.448 to 12.890)15.599 (10.355 to 20.843)
SecondaryChange From Baseline in Pain Domain Scores of LupusQoL at Week 52

The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Pain domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Pain Domain Scores of LupusQoL at Week 52
Units on a scalePlaceboPF-06700841 15 mgPF-06700841 30 mgPF-06700841 45 mg
Change From Baseline in Pain Domain Scores of LupusQoL at Week 5215.065 (10.470 to 19.659)15.480 (9.132 to 21.828)16.855 (12.488 to 21.223)24.418 (19.790 to 29.047)
SecondaryChange From Baseline in Planning Domain Scores of LupusQoL at Week 52

The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Planning domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Planning Domain Scores of LupusQoL at Week 52
Units on a scalePlaceboPF-06700841 15 mgPF-06700841 30 mgPF-06700841 45 mg
Change From Baseline in Planning Domain Scores of LupusQoL at Week 5214.168 (9.423 to 18.912)12.013 (5.487 to 18.538)10.335 (5.826 to 14.843)20.310 (15.523 to 25.097)
SecondaryChange From Baseline in Fatigue Domain Scores of LupusQoL at Week 52

The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Fatigue domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Fatigue Domain Scores of LupusQoL at Week 52
Units on a scalePlaceboPF-06700841 15 mgPF-06700841 30 mgPF-06700841 45 mg
Change From Baseline in Fatigue Domain Scores of LupusQoL at Week 5210.317 (5.951 to 14.683)11.893 (5.892 to 17.894)11.701 (7.550 to 15.853)16.443 (12.036 to 20.850)
SecondaryChange From Baseline in Intimate Relationship Domain Scores of LupusQoL at Week 52

The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Intimate relationship domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Intimate Relationship Domain Scores of LupusQoL at Week 52
Units on a scalePlaceboPF-06700841 15 mgPF-06700841 30 mgPF-06700841 45 mg
Change From Baseline in Intimate Relationship Domain Scores of LupusQoL at Week 5212.430 (6.842 to 18.019)12.625 (4.112 to 21.139)6.494 (0.960 to 12.027)15.363 (9.078 to 21.647)
SecondaryChange From Baseline in Burden to Others Domain Scores of LupusQoL at Week 52

The LupusQoL questionnaire is a validated questionnaire used to evaluate SLE -specific concepts of SLE as reported by participants. It consists of 34 items in 8 different domains: physical health, emotional health, body image, pain, planning, fatigue, intimate relationship, and burden to others measured on a 5-point scale ranging from 0 (not at all) to 4 (very much). The individual domain scores are transformed to a 0 to 100 scale wherein higher scores indicate better quality of life. Burden to others domain score of LupusQoL had score range from 0 to 100, where higher scores = better quality of life.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Burden to Others Domain Scores of LupusQoL at Week 52
Units on a scalePlaceboPF-06700841 15 mgPF-06700841 30 mgPF-06700841 45 mg
Change From Baseline in Burden to Others Domain Scores of LupusQoL at Week 5212.535 (7.227 to 17.842)17.739 (10.412 to 25.065)11.560 (6.500 to 16.621)18.878 (13.523 to 24.233)
SecondaryIncidence Rate of Severe Flare Event

Incidence rate was defined as the number of new events per 100 person-years.

Time frame:
Week 52
Reported as:
Number · Events per 100 person-years
Incidence Rate of Severe Flare Event
Events per 100 person-yearsPlaceboPF-06700841 15 mgPF-06700841 30 mgPF-06700841 45 mg
Incidence Rate of Severe Flare Event8.32 (3.35 to 17.15)6.92 (1.43 to 20.23)3.24 (0.67 to 9.46)6.95 (2.55 to 15.13)
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (AE)

An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. TEAEs are events from first dose of study intervention to 4 weeks after last dose of study intervention that were absent before treatment or that worsened relative to pre-treatment state. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and all non-SAEs.

Time frame:
Day 1 of dosing up to 4 weeks after last dose of study drug (maximum treatment was up to 52 weeks, follow-up up to 56 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (AE)
ParticipantsPlaceboPF-06700841 15 mgPF-06700841 30 mgPF-06700841 45 mg
Number of Participants With Treatment-Emergent Adverse Events (AE)80388883
SecondaryNumber of Participants With Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Time frame:
Day 1 of dosing up to 4 weeks after last dose of study drug (maximum treatment was up to 52 weeks, follow-up up to 56 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs)
ParticipantsPlaceboPF-06700841 15 mgPF-06700841 30 mgPF-06700841 45 mg
Number of Participants With Serious Adverse Events (SAEs)8489
SecondaryNumber of Participants With Adverse Events Leading to Discontinuation From Study

An AE was any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship. In this outcome measure, participants with adverse events leading to discontinuation from study were reported.

Time frame:
Day 1 of dosing up to 4 weeks after last dose of study drug (maximum treatment was up to 52 weeks, follow-up up to 56 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events Leading to Discontinuation From Study
ParticipantsPlaceboPF-06700841 15 mgPF-06700841 30 mgPF-06700841 45 mg
Number of Participants With Adverse Events Leading to Discontinuation From Study6213
SecondaryNumber of Participants With Clinically Significant Vital Signs Abnormalities

Vital signs included blood pressure, pulse rate, respiratory rate, and temperature. Clinical significance in vital signs abnormalities was judged by investigator.

Time frame:
Day 1 of dosing up to 4 weeks after last dose of study drug (maximum treatment was up to 52 weeks, follow-up up to 56 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Vital Signs Abnormalities
ParticipantsPlaceboPF-06700841 15 mgPF-06700841 30 mgPF-06700841 45 mg
Number of Participants With Clinically Significant Vital Signs Abnormalities0000
SecondaryNumber of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities

Clinical significance in ECG abnormalities was judged by investigator.

Time frame:
Day 1 of dosing up to 4 weeks after last dose of study drug (maximum treatment was up to 52 weeks, follow-up up to 56 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities
ParticipantsPlaceboPF-06700841 15 mgPF-06700841 30 mgPF-06700841 45 mg
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities0000
SecondaryNumber of Participants With Laboratory Test Abnormalities

Hematology (Hemoglobin\[hgb\], hematocrit, erythrocytes\[ery\]:\<0.8\*lower limit of normal\[LLN\];reticulocytes, reticulocytes/ery:\<0.5\*LLN,\>1.5\*upper LN\[ULN\];ery mean corpuscular volume\[EMC\], EMC hgb:\<0.9\*LLN,\>1.5\*ULN;EMC hgb concentration:\<0.9\* LLN;platelet:\<0.5\*LLN;leukocytes\[leu\]:\<0.6\*LLN,\>1.5\*ULN;lymphocytes, lymphocytes/leu, neutrophils, neutrophils/leu:\<0.8\* LLN,\>1.2\*ULN;basophils, basophils/leu, eosinophils, eosinophils/leu, monocytes, monocytes/leu:\>1.2\*ULN;activated partial thromboplastin time\[PTT\], PTT, prothrombin time:\>1.1\*ULN);Clinical chemistry (Total/direct/indirect bilirubin, glucose-fasting:\>1.5\*ULN; aspartate aminotransferase\[AT\], alanine AT:\>3.0\*ULN; protein, albumin, HDL cholesterol:\<0.8\*LLN;urea nitrogen, creatinine, triglyceride, cholesterol:\>1.3\*ULN;urate, LDL cholesterol:\>1.2\*ULN;potassium:\<0.9\*LLN,\>1.1\*ULN;calcium, bicarbonate:\<0.9\*LLN;creatine kinase:\>2.0\*ULN);Urinalysis (pH\<4.5;glucose, protein, hgb, ketones, nitrite, leu esterase, granular/hyaline/WBCs casts:\>1).

Time frame:
Day 1 of dosing up to 4 weeks after last dose of study drug (maximum treatment was up to 52 weeks, follow-up up to 56 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Abnormalities
ParticipantsPlaceboPF-06700841 15 mgPF-06700841 30 mgPF-06700841 45 mg
Number of Participants With Laboratory Test Abnormalities96489997

Adverse events

Collected over Day 1 of dosing up to 4 weeks after last dose of study drug (maximum up to 56 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/100 (0%)8/100 (8%)47/100 (47%)
PF-06700841 15 mg0/50 (0%)4/50 (8%)19/50 (38%)
PF-06700841 30 mg1/101 (1%)8/101 (7.9%)53/101 (52.5%)
PF-06700841 45 mg1/99 (1%)9/99 (9.1%)47/99 (47.5%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventPlaceboPF-06700841 15 mgPF-06700841 30 mgPF-06700841 45 mg
Systemic lupus erythematosusMusculoskeletal and connective tissue disorders2/1000/501/1012/99
GastroenteritisInfections and infestations0/1001/500/1010/99
Invasive breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1001/500/1010/99
Thalamic strokeNervous system disorders0/1001/500/1010/99
Lupus pleurisyRespiratory, thoracic and mediastinal disorders0/1001/500/1010/99
HypersensitivityImmune system disorders0/1000/501/1011/99
BacteraemiaInfections and infestations0/1000/500/1011/99
COVID-19Infections and infestations0/1000/501/1011/99
COVID-19 pneumoniaInfections and infestations0/1000/500/1011/99
Transaminases increasedInvestigations0/1000/500/1011/99
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPlaceboPF-06700841 15 mgPF-06700841 30 mgPF-06700841 45 mg
COVID-19Infections and infestations17/1009/5011/10110/99
HeadacheNervous system disorders5/1004/5017/1019/99
Urinary tract infectionInfections and infestations11/1001/5010/10111/99
Upper respiratory tract infectionInfections and infestations7/1001/5011/1018/99
NasopharyngitisInfections and infestations7/1005/506/1018/99
NauseaGastrointestinal disorders5/1004/503/1017/99
DiarrhoeaGastrointestinal disorders5/1001/507/1016/99
Oral candidiasisInfections and infestations0/1000/500/1016/99
VomitingGastrointestinal disorders1/1003/504/1014/99
CystitisInfections and infestations3/1003/502/1012/99

Baseline characteristics

Safety analysis set included all participants who were randomly assigned to study intervention and who took at least 1 dose of study intervention.

Age, Continuous
Age, Continuous(Years)PlaceboPF-06700841 15 mgPF-06700841 30 mgPF-06700841 45 mgTotal
Mean42.5 ± 9.6041.5 ± 11.7942.8 ± 12.7141.0 ± 11.4742.0 ± 11.37
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboPF-06700841 15 mgPF-06700841 30 mgPF-06700841 45 mgTotal
Female94459791327
Male654823
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboPF-06700841 15 mgPF-06700841 30 mgPF-06700841 45 mgTotal
Hispanic or Latino29173435115
Not Hispanic or Latino71326762232
Unknown or Not Reported01023
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboPF-06700841 15 mgPF-06700841 30 mgPF-06700841 45 mgTotal
American Indian or Alaska Native207211
Asian149111347
Native Hawaiian or Other Pacific Islander00000
Black or African American646723
White71316968239
More than one race20002
Unknown or Not Reported568928
08

Study locations

164 sites
  • UAB Department of Medicine Clinical Research Enterprise
    Birmingham, Alabama 35205, United States
  • The Kirklin Clinic
    Birmingham, Alabama 35233, United States
  • UAB Hospital Department of Pharmacy
    Birmingham, Alabama 35249, United States
  • UAB Hospital-Clinical Research Unit (CRU)
    Birmingham, Alabama 35249, United States
  • The University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • UAB Department of Medicine Clinical Research Enterprise
    Birmingham, Alabama 35294, United States
  • St. Joseph Heritage Healthcare
    Fullerton, California 92835, United States
  • Advanced Medical Research, LLC
    La Palma, California 90623, United States
  • Arthritis and Osteoporosis Medical Center
    La Palma, California 90623, United States
  • Desert Medical Advances
    Palm Desert, California 92260-9368, United States
  • East Bay Rheumatology Medical Group, Inc.
    San Leandro, California 94578, United States
  • Millennium Clinical Trials
    Thousand Oaks, California 91360, United States
  • Inland Rheumatology and Osteoporosis Medical Group
    Upland, California 91786, United States
  • Inland Rheumatology Clinical Trials, Inc.
    Upland, California 91786, United States
  • New England Research Associates, LLC
    Bridgeport, Connecticut 06606, United States
  • New England Research Associates
    Bridgeport, Connecticut 06606, United States
  • Stamford Therapeutics Consortium
    Stamford, Connecticut 06905, United States
  • Clinical Research of West Florida
    Clearwater, Florida 33765, United States
  • Private Practice of Robert W. Levin
    Clearwater, Florida 33765, United States
  • SIMEDHealth, LLC Attn: Rheumatology
    Gainesville, Florida 32607, United States
  • SIMEDHealth, LLC
    Gainesville, Florida 32607, United States
  • Omega Research MetroWest, LLC
    Orlando, Florida 32808, United States
  • Akumin, Inc
    Palm Harbor, Florida 34685, United States
  • Akumin Inc
    Saint Petersburg, Florida 33703, United States
  • West Broward Rheumatology Associates, Inc
    Tamarac, Florida 33321, United States
  • Akumin Inc.
    Tampa, Florida 33603, United States
  • Rose Radiology dba Akumin Inc.
    Tampa, Florida 33603, United States
  • Clinical Research of West Florida
    Tampa, Florida 33606, United States
  • AdventHealth Tampa
    Tampa, Florida 33613, United States
  • Jefrey D. Lieberman, M.D., P.C.
    Decatur, Georgia 30033, United States
  • Atlanta Research Center for Rheumatology
    Marietta, Georgia 30060, United States
  • Institute of Arthritis Research
    Idaho Falls, Idaho 83404, United States
  • Investigational Drug Services University of Kansas Hospital
    Kansas City, Kansas 66103, United States
  • The University of Kansas Hospital
    Kansas City, Kansas 66160, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Ochsner Clinic Foundation, Baton Rouge
    Baton Rouge, Louisiana 70836, United States
  • University of Michigan Brighton Center for Specialty Care
    Brighton, Michigan 48116, United States
  • Innovative health Research
    Las Vegas, Nevada 89128, United States
  • NYU Langone Ambulatory Care Brooklyn Heights
    Brooklyn, New York 11201, United States
  • St. Lawrence Health System
    Canton, New York 13617, United States
  • Feinstein Institute for Medical Research
    Manhasset, New York 11030, United States
  • Northshore University Hospital
    Manhasset, New York 11030, United States
  • Columbia University Medical Center.
    New York, New York 10032, United States
  • Irving Institute for Clinical and Transitional Research
    New York, New York 10032, United States
  • St. Lawrence Health System
    Potsdam, New York 13676, United States
  • Joint and Muscle Research Institute
    Charlotte, North Carolina 28204, United States
  • Arthritis & Rheumatology Center of Oklahoma PLLC
    Oklahoma City, Oklahoma 73102, United States
  • West Tennessee Research Institute
    Jackson, Tennessee 38305, United States
  • Gupta, Ramesh C MD
    Memphis, Tennessee 38119-5214, United States
  • Tekton Research
    Austin, Texas 78745, United States
  • Accurate Clinical Management, LLC
    Baytown, Texas 77521, United States
  • Rheumatic Disease Clinical Research Center, LLC
    Houston, Texas 77004, United States
  • Accurate Clinical Research
    Houston, Texas 77089, United States
  • Arthritis Clinic of Central Texas
    San Marcos, Texas 78666, United States
  • Arthritis Northwest, PLLC
    Spokane, Washington 99204, United States
  • Centro de Investigaciones Medicas Tucuman
    San Miguel de Tucuman, Tucuman T4000AXL, Argentina
  • Optimus Clinical Research
    Kogarah, New South Wales 2217, Australia
  • Emeritus Research
    Camberwell, Victoria 3124, Australia
  • UZ Leuven
    Leuven, 3000, Belgium
  • Ziekenhuisnetwerk Antwerpen Jan Palfijn (ZNA Jan Palfijn)
    Merksem, 2170, Belgium
  • DCC Sveti Georgi EOOD
    Plovdiv, 4000, Bulgaria
  • MHAT Plovdiv AD
    Plovdiv, 4000, Bulgaria
  • Umhat Kanev Ad
    Ruse, 7002, Bulgaria
  • UMHAT "Sv.Ivan Rilski" EAD
    Sofia, 1431, Bulgaria
  • UMHAT "Sv. Ivan Rilski" EAD
    Sofia, 1432, Bulgaria
  • Centre intégré de santé et de services sociaux du Bas-Saint-Laurent
    Rimouski, Quebec G5L 5T1, Canada
  • Centre de Recherche Musculo-Squelettique
    Trois-Rivieres, Quebec G8Z 1Y2, Canada
  • Anhui Provincial Hospital
    Hefei, Anhui 230001, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan 410011, China
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215006, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin 300052, China
  • Peking Union Medical College Hospital
    Beijing, 100730, China
  • Ruijin Hospital- Shanghai Jiaotong University School of Medicine
    Shanghai, 200025, China
  • Fudan University Hua Shan Hospital
    Shanghai, 200040, China
  • Hospital Pablo Tobon Uribe
    Medellin, Antioquia 050034, Colombia
  • Centro Integral de Reumatología del Caribe S.A.S - CIRCARIBE S.A.S
    Barranquilla, Atlantico 080002, Colombia
  • Bluecare Salud S.A.S Sede Centro Médico Integral Chicó MedPlus CRI
    Bogota, Cundinamarca 110221, Colombia
  • Centro de Investigación en Reumatología y Especialidades Médicas SAS - CIREEM SAS
    Bogotá, Cundinamarca 110221, Colombia
  • Medicity S.A.S.
    Bucaramanga, Santander 680003, Colombia
  • Vseobecna fakultni nemocnice v Praze
    Praha 2, 128 08, Czechia
  • Nemocnicni lekarna VFN
    Praha 2, 12802, Czechia
  • Revmatologicky ustav
    Praha 2, 12850, Czechia
  • Hôpital Pitié Salpêtrière, Centre des Maladies Auto-immunes
    Paris, 75013, France
  • Hôpital Cochin
    Paris, 75014, France
  • CHU de Bordeaux, Groupe Hospitalier Sud, Hôpital Haut Lévèque
    Pessac, 33604, France
  • Medizinische Hochschule Hannover
    Hannover, 30625, Germany
  • Universitätsklinikum Schleswig Holstein - Campus Lübeck
    Lübeck, 23538, Germany
  • University General Hospital of Heraklion
    Heraklion, Crete 71110, Greece
  • Laiko General Hospital, University of Athens
    Athens, 11527, Greece
  • University Hospital ATTIKON
    Haidari, 12462, Greece
  • Tuen Mun Hospital
    Hong Kong, Hong Kong
  • Qualiclinic Kft.
    Budapest, 1036, Hungary
  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, 4032, Hungary
  • Békés Vármegyei Központi Kórház
    Gyula, 5700, Hungary
  • Fondazione IRCCS Policlinico S.Matteo
    Pavia, 27100, Italy
  • National Hospital Organization Asahikawa Medical Center
    Asahikawa, Hokkaido 070-8644, Japan
  • Hokkaido University Hospital
    Sapporo, Hokkaido 060-8648, Japan
  • Tohoku University Hospital
    Sendai, Miyagi 980-8574, Japan
  • Sasebo Chuo Hospital
    Sasebo, Nagasaki 857-1195, Japan
  • Shinkenko clinic
    Naha, Okinawa 900-0015, Japan

Showing the first 100 of 164 sites across 26 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Hannon CW, McCourt C, Lima HC, Chen S, Bennett C. Interventions for cutaneous disease in systemic lupus erythematosus. Cochrane Database Syst Rev. 2021 Mar 9;3(3):CD007478. doi: 10.1002/14651858.CD007478.pub2. PubMed 33687069 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Oct 2023, 53 months.

Results were first posted in Sep 2024, 11 months after primary completion.

Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's 53 months is above that.

Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2019
First posted
Feb 19, 2019
StartActual
Apr 18, 2019
Primary completionActual
Oct 5, 2023
CompletionActual
Oct 5, 2023
Results first posted
Sep 5, 2024
Last update
Sep 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03845517
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Feb 19, 2019
Start date
Apr 18, 2019
Primary completion
Oct 5, 2023
Completion
Oct 5, 2023
Results posted
Sep 5, 2024
Last update
Sep 5, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-06700841

Start the discussion